Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model.
Mullerian inhibiting substance (MIS) inhibits breast cancer cell growth in vitro. To extend the use of MIS to treat breast cancer, it is essential to test the responsiveness of mammary tumor growth to MIS in vivo. Mammary tumors arising in the C3(1) T antigen mouse model expressed the MIS type II receptor, and MIS in vitro inhibited the growth of cells derived from tumors. Administration of MIS to mice was associated with a lower number of palpable mammary tumors compared with vehicle-treated mice (P=0.048), and the mean mammary tumor weight in the MIS-treated group was significantly lower compared with the control group (P=0.029). Analysis of proliferating cell nuclear antigen (PCNA) expression and caspase-3 cleavage in tumors revealed that exposure to MIS was associated with decreased proliferation and increased apoptosis, respectively, and was not caused by a decline in T antigen expression. The effect of MIS on tumor growth was also evaluated on xenografted human breast cancer cell line MDA-MB-468, which is estrogen receptor- and retinoblastoma-negative and expresses mutant p53, and thus complements the C3(1)Tag mouse mammary tumors that do not express estrogen receptor and have functional inactivation of retinoblastoma and p53. In agreement with results observed in the transgenic mice, MIS decreased the rate of MDA-MB-468 tumor growth and the gain in mean tumor volume in severe combined immunodeficient mice compared with vehicle-treated controls (P=0.004). These results suggest that MIS can suppress the growth of mammary tumors in vivo.
Gupta
V
V
Department of Surgical Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.
Carey
J L
JL
Kawakubo
H
H
Muzikansky
A
A
Green
J E
JE
Donahoe
P K
PK
MacLaughlin
D T
DT
Maheswaran
S
S
D000818:Animals; D054304:Anti-Mullerian Hormone; D000941:Antigens / Q000276:immunology / Q000502:physiology*; D017209:Apoptosis / Q000502:physiology; D002455:Cell Division / Q000502:physiology; D003176:Complement C3 / Q000502:physiology*; D006023:Glycoproteins / Q000502:physiology*; D008325:Mammary Neoplasms, Experimental / Q000276:immunology / Q000473:pathology*; D051379:Mice; D016513:Mice, SCID; D008822:Mice, Transgenic; D013735:Testicular Hormones / Q000502:physiology*
D000941:Antigens; D003176:Complement C3; D006023:Glycoproteins; D013735:Testicular Hormones; D054304:Anti-Mullerian Hormone
Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):239-44
11773638
J Immunol. 2001 Jan 15;166(2):1156-68
11145697
Semin Cancer Biol. 2000 Apr;10(2):125-44
10936063
Mol Cell Endocrinol. 2003 Dec 15;211(1-2):43-9
14656475
Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15601-6
14671316
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3214-9
11248058
Mol Endocrinol. 2001 Jun;15(6):946-59
11376113
Oncogene. 2000 Feb 21;19(8):1020-7
10713685
N Engl J Med. 1992 Feb 13;326(7):466-71
1732773
Clin Cancer Res. 2002 Aug;8(8):2640-6
12171896
J Clin Endocrinol Metab. 1996 Feb;81(2):571-6
8636269
J Biol Chem. 2000 Nov 24;275(47):37101-9
10958795
Nat Genet. 2002 Nov;32(3):408-10
12368913
Cell. 1989 Jul 28;58(2):249-55
2546678
Endocr Rev. 2001 Oct;22(5):657-74
11588147
J Biol Chem. 2000 Sep 8;275(36):27973-8
10854429
EMBO J. 1992 Dec;11(13):5013-20
1464323
Development. 1994 Jan;120(1):189-97
8119126
J Biol Chem. 2000 Sep 15;275(37):28371-9
10874041
Ann Oncol. 1994;5 Suppl 4:31-7
7914742
Endocrinology. 1996 Jan;137(1):160-5
8536608
J Biol Chem. 2001 Jul 20;276(29):26799-806
11356848
Mol Endocrinol. 1994 Aug;8(8):1006-20
7997230
Mol Endocrinol. 2001 Jun;15(6):936-45
11376112
Anticancer Res. 2001 Jan-Feb;21(1A):413-20
11299771
Breast. 2000 Oct;9(5):239-46
14732173
Protein Expr Purif. 1992 Jun;3(3):236-45
1392620
J Biol Chem. 2003 Dec 19;278(51):51703-12
14532292
J Clin Endocrinol Metab. 1990 Jan;70(1):16-22
2294129